{"filing":{"accession_number":"0001193125-26-336843","cik":"0001810182","ticker":"ALXO","company_name":"ALX ONCOLOGY HOLDINGS INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"alxo-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/alxo-20260806.htm"},"events":[{"id":25562,"run_id":23202,"accession_number":"0001193125-26-336843","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ALX Oncology issued a press release on August 6, 2026, announcing its financial results for the second quarter ended June 30, 2026, including consolidated statements of operations, balance sheet data, and per-share metrics. The disclosure includes GAAP net loss of ($17.971) million and non-GAAP net loss of ($14.310) million for Q2 2026, along with cash position of $153.4 million and detailed operating expense breakdowns. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26431,"accession_number":"0001193125-26-336843","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ALX Oncology issued a press release on August 6, 2026, announcing its financial results for the second quarter ended June 30, 2026, including consolidated statements of operations, balance sheet data, and per-share metrics. The disclosure includes GAAP net loss of ($17.971) million and non-GAAP net loss of ($14.310) million for Q2 2026, along with cash position of $153.4 million and detailed operating expense breakdowns. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:18.120298+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26431,"accession_number":"0001193125-26-336843","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ALX Oncology issued a press release on August 6, 2026, announcing its financial results for the second quarter ended June 30, 2026, including consolidated statements of operations, balance sheet data, and per-share metrics. The disclosure includes GAAP net loss of ($17.971) million and non-GAAP net loss of ($14.310) million for Q2 2026, along with cash position of $153.4 million and detailed operating expense breakdowns. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:55:18.120298+00:00","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-08-06"}]}